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were obtained from ofﬁcial sources, while the rest of data
were taken from a national Health care-cost database.
The perspective selected for this analysis was hospital
assistance and the time horizon chosen was for 12 weeks,
the time that patients were followed up in the referenced
clinical trial. RESULTS: The probability of successful
treatment of VOR was higher than with AMB (52.8 vs.
31.6%, p < 0.05), while the cost/effectiveness ratio was
lower with VOR compared with AMB: €60,577 vs.
€84,294 per each patient with successful outcome. CON-
CLUSIONS: This pharmacoeconomic analysis shows that
VOR is a more efﬁcient therapeutic option than AMB, as
its cost/effectiveness ratio is lower. Therefore, VOR could
be considered as the therapeutic option to be selected rou-
tinely in the treatment of invasive aspergillosis in
immunosupressed patients in Spain.
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Fuzeon® (enfuvirtide; ENF), formerly know as T-20, is
the ﬁrst drug from a novel class of antiretroviral known
as the HIV fusion inhibitors which has shown high efﬁ-
cacy rates in HIV-1 / AIDS patients who are resistant to
conventional antiretroviral (ARV) agents. OBJECTIVE:
To analyse the efﬁcacy of adding ENF to an optimised
background regimen (OB) in HIV patients. A Markov
model was developed to establish the cost-effectiveness of
ENF in terms of incremental cost per life year gained
(LYG). The model was designed over a time horizon of
10 years with monthly cycles. The analysis was performed
from the perspective of the Spanish NHS. The primary
clinical outcome was time until death. Efﬁcacy rates and
transition probabilities were obtained from reported clin-
ical and epidemiological trials. Resource use data was
retrieved from published literature and from advise from
a panel of 6 clinical opinion leaders. Unit costs for Spain
in Euros 2003 were obtained from published sources.
RESULTS: Adding ENF to OB increases patient’s life
expectancy by 1.6 years (4.6 years with OB vs. 6.2 years
with ENF + OB). Total costs are €116,718 for OB and
€155,674 with ENF + OB, mainly due to the fact that
increasing life expectancy for a given cohort of patients
increases resource use and costs. CONCLUSIONS:
Incremental cost per life year gained with ENF is €24,780.
ENF used in combination with an OB regimen increases
life expectancy for HIV-1 treated patients who are highly
ARV-experienced, resulting in an economically efﬁcient
treatment option.
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OBJECTIVES: In 2004, the concept of diagnosis-related-
groups (DRG) will be implemented in the reimbursement
procedure of German hospitals. Presently, the hospitals
are reimbursed on a daily lump sum basis. To evaluate
the treatment costs of community-acquired pneumonia
(CAP) from the hospital’s perspective, a prospective
health economic study has been in progress since the end
of 2002. An interim analysis revealed ﬁrst cost results.
METHODS: Open, non-randomized prospective obser-
vational study from the perspective of the German hos-
pital administration. From 6 study centres, 84 patients
were enrolled. A total number of 300 patients is foreseen.
A process-cost-analysis was performed to determine the
costs for the German hospital sector starting from the
admission up to the discharge of the patient. The cost cal-
culation comprises diagnostic and therapeutic measures,
drugs, hotel costs and nursing. Both personnel costs and
material costs were included. Due to the dualistic hospi-
tal reimbursement system, acquisition values of medical
devices were not included into the analysis. RESULTS:
The enrolled patients suffered from moderate to severe
stages of CAP with a mean length-of-stay of 11.7 days
(peripheral ward: 11.2; ICU 0.5). Mean costs per patient
amounted to €2204 (SD: €1654). The most important
cost-driving factor was nursing, amounting to mean costs
of €902, followed by hotel costs amounting to €666.
Drug acquisition cost resulted in €291, whereas costs for
diagnostics (€163) and therapeutic measures (€181) were
comparatively low. According to the actual German
ﬁnancing procedure (based on length-of-stay/lump sum
per day), a hospital would be reimbursed with approxi-
mately €2990 per patient with CAP. CONCLUSIONS:
Before the implementation of the DRG system into the
hospital reimbursement procedure, the treatment of CAP
is proﬁtable from the hospital’s perspective. This will
probably change after the implementation of the DRG-
based reimbursement.
